
In SURMOUNT-ADOLESCENTS, tirzepatide cut BMI 18.5% at 72 weeks vs a 0.5% rise with placebo in adolescents with obesity.
Morgan Ebert is executive editor Contemporary Pediatrics®. She joined the MJH Life Sciences team in December 2019. She graduated from Youngstown State University in 2019 with a bachelor's degree in journalism and a minor in political science. Prior to graduating, Morgan worked as the editor-in-chief of her college newspaper. She went on to work as an assignment editor at a broadcast news station in Youngstown, Ohio, before joining Contemporary Pediatrics. You can reach her at mebert@mjhlifesciences.com.

In SURMOUNT-ADOLESCENTS, tirzepatide cut BMI 18.5% at 72 weeks vs a 0.5% rise with placebo in adolescents with obesity.

Caregivers reported itch, symptom, and QOL gains with roflumilast cream 0.05% in infants with AD; an FDA decision is due February 2027.

Novo Nordisk filed etavopivat for SCD in patients aged 12+, backed by phase 3 HIBISCUS data showing a 27% drop in vaso-occlusive crises vs placebo.

In STEP Young, semaglutide cut BMI 13.5% at 68 weeks vs a 2.7% rise with placebo in children aged 6 to <12 years with obesity.

Schools without stock epinephrine were over 4 times as likely to lack a device in an allergic emergency, a survey of 349 school nurses found.

In a matched cohort of children aged 6 and younger with EoE, dupilumab was linked to less incident asthma than swallowed budesonide (10.5% vs 16.2%).

Non-English-speaking families were far less likely to introduce peanut by 6 months (OR, 0.21) in a 3,170-child study presented at ACAAI 2026.

In an ACAAI 2026 survey, 85% of clinicians knew food allergy panels often yield false positives, yet many ordered them for unvalidated uses.

Full OptIMMize-1 results show high skin clearance rates with risankizumab in children and teens with psoriasis, sustained through 52 weeks.

Children living more than 60 miles from their surgical hospital had higher complication odds and longer stays after common procedures.

Emily Becker, MD, discusses the role of AhR agonists, skin barrier function, and steroid-free treatment options for pediatric atopic dermatitis.

Post hoc data show cariprazine improved both manic and depressive symptoms through 52 weeks in youth aged 10 to 17 years with bipolar I disorder.

CDC data show pediatric CP-CRE incidence rose 92% from 2019 to 2024, driven by NDM-CRE, mostly in children with complex medical needs.

A meta-analysis of 52 studies links NO2, SO2, and particulate matter to more pediatric atopic dermatitis visits and higher prevalence.

A meta-analysis of 7 real-world studies found maternal RSVpreF 78% effective against RSV LRTI hospitalization in infants up to 6 months.

In 5.2 million US infants, newborn vitamin K nonreceipt rose to 6.8% by 2025 and was tied to a 47% higher bleeding risk by 6 months.

New real-world data reveal delays and disparities in nirsevimab administration, highlighting opportunities to improve timely RSV protection for infants.

Find out the 4 FDA decisions to watch in November 2026 for pediatric care.

Cenobamate sNDAs target PGTC seizures in patients ≥12 years and pediatric focal seizures; phase 3 PGTC data showed a 71.9% median reduction.

FDA approved Lupin's generic of Firdapse for LEMS in patients 6 years and older, but a patent settlement delays US marketing until at least 2035.

CDC confirmed the first pediatric flu death of 2026-27, linked to H1N1, as early flu activity rises in 2026.

Pumpkin carving accounts for 55% of Halloween ED injuries; AAOS outlines prevention tips for carving, costumes, and trick-or-treating.

NHIS data show the share of US children aged 5 to 17 years ever diagnosed with ADHD climbed from 9.9% in 2019 to 13.8% in 2025.

A proposed rule would revise iodine, manganese, and vitamin A and D levels in infant formula and reaffirm 4 other nutrient specifications.

A review of 93 studies links pediatric home-based hospice and palliative care to fewer hospital days, lower costs, and better family QOL.

With California WNV activity at a 5-year high, CHLA outlines age-based repellent and bite-prevention guidance for children.

AHA, AAP, ACOG, and SMFM issued a Female Life Stage framework that starts cardiovascular risk assessment at perimenarche, around ages 8 to 15.

In PROGRESS Cohort 2, zilurgisertib reduced total HO volume vs placebo at 24 weeks in children aged 6 to 11 with FOP, with no new HO lesions.

Registry data presented at ASN Kidney Week 2026 linked SCD-PED to higher 90-day survival vs historical controls in pediatric sepsis-associated AKI.

The FDA approved insulin icodec-abae for children 10+ with T2D, based on adult ONWARDS data and a single-dose pediatric pharmacokinetic study.

September 2nd 2026

May 9th 2022